GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Shenzhen YHLO Biotech Co 688575.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

10.97

-0.99%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Shenzhen YHLO Biotech Co

Its shares trade on Shanghai under the ticker 688575.SS. It has been listed since 17 May 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.81bn and net income of CN¥24.0m. At that date it held total assets of CN¥4.29bn and shareholders' equity of CN¥2.70bn.

Shenzhen YHLO Biotech Co., Ltd. engages in the research and development, production and sales of in vitro diagnostic instruments and supporting reagents based on chemiluminescence immunoassay solution for diagnosis of autoimmune diseases, reproductive health, and infectious diseases. The company is headquartered in Shenzhen, Guangdong. The company went IPO on 2021-05-17. The firm's products are applied in autoimmunity, reproductive health, diabetes and infectious disease fields. The firm's main products include in-vitro diagnostic instruments and supporting reagents based on chemiluminescence, immunoblotting, enzyme-linked immunoassay, immunofluorescence chromatography and other methodologies. The firm distributes its products in domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Health Care Equipment & Supplies
Listed since
17 May 2021
Employees
1,837
Website
szyhlo.com ↗

Leadership

Pay as last reported

  • Mr. Kunhui HuChairman of the Board, since 2021
  • Mr. Yongbo SongVice Chairman of the Board, General Manager, since 2021
  • Mr. Lisheng LiaoChief Financial Officer, Director, since 2022
  • Mr. Chungen QianDeputy General Manager, Director, since 2021
  • Mr. Mingyang WangSecretary of the Board
  • Mr. Yi ZhouDirector
  • Mr. Xuejin LiIndependent Director
  • Mr. Dengming LiuIndependent Director
  • Mr. Shunwen ZhangIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Shenzhen YHLO Biotech employs 1837 full-time staff members in Shenzhen.
  • The company produces in-vitro diagnostic instruments for autoimmune diseases.
  • Supporting reagents utilize chemiluminescence immunoassay solution technology.

Weaknesses

  • The firm lists its shares on the market since 17 May 2021.
  • Products are applied in the diabetes field segment.
  • Immunoblotting methodology is part of the main product range.

Opportunities

  • The company distributes products to overseas markets globally.
  • Reproductive health diagnostics represent a key application area.
  • Infectious disease testing drives demand for reagents.

Threats

  • Enzyme-linked immunoassay competes with chemiluminescence methods.
  • Immunofluorescence chromatography offers alternative diagnostic solutions.
  • Domestic market competition affects sales performance.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.